Edition:
India

Teva Pharmaceutical Industries Ltd (TEVA.N)

TEVA.N on New York Stock Exchange

33.03USD
27 Mar 2017
Change (% chg)

-- (--)
Prev Close
$33.03
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,103,728
52-wk High
$58.15
52-wk Low
$31.91

TEVA.N

Chart for TEVA.N

About

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic... (more)

Overall

Beta: 0.63
Market Cap(Mil.): $32,775.40
Shares Outstanding(Mil.): 1,014.36
Dividend: 0.34
Yield (%): 4.12

Financials

  TEVA.N Industry Sector
P/E (TTM): 213.21 29.25 30.03
EPS (TTM): 0.15 -- --
ROI: 0.53 13.69 13.19
ROE: 0.24 14.58 14.33

UPDATE 1-Teva Pharm says media reports of up to 6,000 layoffs incorrect

JERUSALEM, March 23 Teva Pharmaceutical Industries' plans to end unprofitable activities and freeze recruitment, but said Israeli media reports of up to 6,000 layoffs were incorrect.

23 Mar 2017

Teva Pharm may fire 6,000 workers -Israeli media report

JERUSALEM, March 23 Teva Pharmaceutical Industries may fire as many as 6,000 workers worldwide as part of a multi-year efficiency plan, Israel's Calcalist news website reported on Thursday.

23 Mar 2017

BRIEF-OncBioMune announces term sheet to acquire Norepinefrine from Teva Pharmaceuticals in Mexico

* OncBioMune announces term sheet to acquire Norepinefrine from Teva Pharmaceuticals in Mexico

20 Mar 2017

Teva Pharm sells shares in Gamida Cell, raises stake in Clal Biotech

* Teva Pharmaceutical Industries has agreed to sell a small stake in Israel-based Gamida Cell and in return will increase its holdings in Clal Biotechnology, the companies said on Sunday.

05 Mar 2017

BRIEF-Teva says FDA granted priority review for SD-809 for treatment of tardive dyskinesia

* Teva Pharmaceutical Industries Ltd - FDA has assigned a prescription drug user fee act (PDUFA) goal date of August 30, 2017.

28 Feb 2017

Marcato's McGuire criticizes Deckers' retail expansion: CNBC

NEW YORK Mick McGuire, founder of activist hedge fund Marcato Capital Management, told CNBC on Monday that Deckers Outdoor Corp had erred by investing significantly in physical retail stores.

14 Feb 2017

UPDATE 1-Marcato's McGuire criticizes Deckers' retail expansion -CNBC

NEW YORK, Feb 13 Mick McGuire, founder of activist hedge fund Marcato Capital Management, told CNBC on Monday that Deckers Outdoor Corp had erred by investing significantly in physical retail stores.

14 Feb 2017

BRIEF-Teva said to weigh options for branded generics to reduce debt- Bloomberg, citing sources

* Teva said to weigh options for branded generics to reduce debt - Bloomberg, citing sources

13 Feb 2017

Teva seeks CEO with pharma background to lead recovery efforts

TEL AVIV Teva Pharmaceutical Industries is seeking a new chief executive with deep drug industry experience, the Israel-based company said on Monday as it looks to restore confidence after a series of missteps and the departure of CEO Erez Vigodman.

13 Feb 2017

UPDATE 2-Teva seeks CEO with pharma background to lead recovery efforts

* Shares in New York up 4 percent in early trade (Recasts with comments about CEO, adds details from conference call, analyst)

13 Feb 2017

More From Around the Web

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF74.05 +0.20
Biogen Inc (BIIB.OQ) $275.23 --

Earnings vs. Estimates